relapsed/refractory B-cell non-Hodgkin lymphoma
Showing 1 - 25 of >10,000
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)
Not yet recruiting
- Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- JS203 for Injection
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Nov 11, 2022
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,
Recruiting
- Lymphoma, Non-Hodgkin
- +6 more
- CB-010
- +2 more
-
Scottsdale, Arizona
- +7 more
Aug 19, 2022
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Selinexor, Flu, CTX)
Recruiting
- Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Selinexor
- +3 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Apr 3, 2022
B-cell Non-Hodgkin's Lymphoma Trial in Hangzhou (CD19-CAR-DNT cells)
Recruiting
- B-cell Non-Hodgkin's Lymphoma
- CD19-CAR-DNT cells
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 6, 2022
Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- BTK inhibitor
- PD-1 inhibitor
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023
B-cell NHL, CLL Trial (CARCIK-CD19)
Not yet recruiting
- B-cell NHL
- CLL
- CARCIK-CD19
- (no location specified)
May 19, 2023
Non-hodgkin Lymphoma Trial (HY004)
Not yet recruiting
- Non-hodgkin Lymphoma
- HY004
- (no location specified)
Aug 21, 2023
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)
Not yet recruiting
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- (no location specified)
Mar 23, 2023
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Odronextamab
- +8 more
- (no location specified)
Aug 7, 2023
CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)
Recruiting
- CD20-positive B-cell Non-Hodgkin's Lymphoma
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- +2 more
- (no location specified)
Jun 22, 2023
Lymphoma, Non-Hodgkin Trial in Perth (DZD8586)
Not yet recruiting
- Lymphoma, Non-Hodgkin
-
Perth, Western Australia, AustraliaLinear Clinical Research Ltd
Apr 20, 2023
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide
Active, not recruiting
- Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Brexucabtagene Autoleucel (KTE-X19)
- +2 more
-
Los Angeles, California
- +30 more
Nov 2, 2022
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023